PFIZER INC annual report, FY2019

Full document

Pfizer Inc. 2019 Form 10-K Summary

Business context and reporting period

Annual report for the fiscal year ended December 31, 2019. Pfizer is a global research-based biopharmaceutical company selling products in more than 125 countries. In 2019, it managed operations through Biopharma, Upjohn and, through July 31, Consumer Healthcare. Consumer Healthcare was combined with GSK’s business into a joint venture; Pfizer retained a 32% stake. Pfizer also announced a planned combination of Upjohn with Mylan, expected to close in mid-2020, subject to approvals and other conditions.

Financial and operating metrics

  • 2019 revenue was approximately $51.8 billion. Biopharma revenue was approximately $39.4 billion and Upjohn revenue approximately $10.2 billion.
  • Revenue from outside the U.S. was $27.9 billion, or 54% of total revenue.
  • Research and development expense was approximately $8.7 billion. Pfizer reported 95 projects in clinical research and development as of January 28, 2020.
  • Eight biopharmaceutical products each generated more than $1 billion in direct product and/or alliance revenue and together represented 49% of total revenue.
  • The supplied filing text does not provide clear consolidated net income, cash flow, margins, debt balances or liquidity figures. Those financial statements and related MD&A are incorporated by reference from the 2019 Financial Report.

Material changes versus the prior comparable period

  • Pfizer acquired Array BioPharma in July 2019 for approximately $11.2 billion in total consideration, or $10.9 billion net of cash acquired.
  • Pfizer completed the Consumer Healthcare joint venture with GSK on July 31, 2019, receiving a 32% equity interest.
  • Pfizer announced the proposed Upjohn-Mylan combination in July 2019. The transaction was still pending at year-end; Pfizer estimated approximately $500 million in separation costs, including $145 million incurred in 2019.
  • Lyrica lost U.S. patent protection in June 2019, with multi-source generic competition beginning in July. Lyrica revenue in markets affected by exclusivity loss was $2.208 billion in 2019, versus $3.852 billion in 2018 and $3.901 billion in 2017.
  • Pfizer said it expected significant revenue effects from patent expiries in 2020, moderating to a much lower level during 2021–2025. Chantix’s basic U.S. product patent was due to expire in November 2020.

Outlook, commentary, risks and unusual items

  • The filing refers to 2020 financial guidance, but the supplied text does not state its numerical values.
  • Management described the company as transitioning toward a more focused business centered on innovative medicines. Execution of the Upjohn separation and combination, and realization of expected transaction benefits, remained uncertain.
  • Key risks include pricing and reimbursement pressure, generic and biosimilar competition, loss of exclusivity, dependence on leading products, R&D and regulatory uncertainty, foreign exchange exposure, and reliance on wholesalers and third-party collaborators.
  • China’s volume-based procurement and generic competition created pressure on Upjohn and Biopharma products. Pfizer noted that its Upjohn business was unsuccessful in key bidding rounds and anticipated continued effects.
  • Manufacturing and regulatory risks included ongoing FDA scrutiny and an Official Action Indicated classification at the McPherson site, as well as potential product shortages and production issues. Pfizer specifically noted Genotropin production issues expected to reduce revenue.
  • Pfizer identified the emerging COVID-19 outbreak as a potential risk to manufacturing, supply chain, sales, marketing and clinical trials; the eventual impact was uncertain.
  • Other notable exposures include legal and patent proceedings, environmental remediation, data privacy and cybersecurity risks, and regulatory and pricing changes. The filing also disclosed a five-year Corporate Integrity Agreement effective from May 2018.

Important facts for investors to verify

  • Review the incorporated 2019 Financial Report for full income statement, cash flow, balance sheet, debt, liquidity and year-over-year performance details.
  • Check the numerical 2020 guidance and the assumptions underlying expected patent-expiry and pricing impacts.
  • Monitor regulatory approvals, closing conditions, costs and separation timing for the Upjohn-Mylan transaction, as well as Pfizer’s continuing 32% interest in the GSK Consumer Healthcare joint venture.
  • Assess the revenue trajectory of major products after Lyrica’s U.S. generic launch and the expected Chantix U.S. patent expiry, alongside growth and competition affecting leading Biopharma products.
  • Track developments in China procurement and pricing, FDA manufacturing-site status and supply continuity, and the potential operational effects of COVID-19.